Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. - Wikidata - awgldk - TriplyDB

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.

http://www.wikidata.org/entity/Q50758911

about

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Tumor necrosis factor inhibitors in psoriatic arthritis.Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus.Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients.The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis.A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer.Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.

P2860

Q26774173-1910AE53-DAC5-4822-8E88-ABAAAA0DA083 Q27012134-AA1A0118-15B0-4EFA-A684-8665CA9390F7 Q28546596-B0B39CC1-4CE0-4C19-AC33-338D05CF1E8B Q30240229-838EF021-C385-4C86-8B45-1EB5C5A45513 Q30995889-36147E5E-1E6C-4F07-9BC3-CE7F6EB26C15 Q31085610-8F2072AC-A06E-4603-AA7A-491BC6339BFF Q34669637-06E3C740-45E5-4511-A2C3-CE7AE8BF8541 Q35544546-59D000A9-A13B-448B-9026-5D49F1DA5732 Q35592110-3F344863-A7FE-4DCE-A90D-F5B583E01049 Q36231590-83D2C963-C2CA-4DFA-84DA-A5EEED1AAEC2 Q36485893-ECDC5C93-0411-4C73-8941-940BB1CB39AB Q36776326-1DCAE587-52FE-4F06-8EC1-E2BD85C6474A Q37616966-E25B73D3-25DF-456A-A959-84699445626C Q37690355-22DD5618-4303-4BD4-ACA9-EC67C850BE4A Q38129037-7163D11C-DD6D-4004-BF00-0888A1F165CE Q38150903-240A03FA-7C03-472F-B12F-8365E77C834A Q38151885-8BF730DB-C5C6-4547-B351-E6F55C68D5C5 Q38200926-5C9098F7-61C4-4247-A8F6-6BE075C35869 Q38212907-35D40B3B-460C-4645-88D3-974DF4E51B3E Q38631012-AD673114-A910-43BA-A702-AF41A53ABB83 Q38685543-4A1CAE63-23A8-470A-B380-6E8157AAF789 Q38711954-647F0CEA-5F82-4B8F-B8D3-F720AA825FD8 Q39371316-236AC431-F641-4AE2-8D65-487E51A3609E Q40624064-602C9653-DEEB-43CF-8452-31E606C3DCCE Q41015565-5881F7A1-2C07-422A-8337-6D8B651D4B68 Q41359123-BD86E899-5866-491C-8EB8-21743F54A78C Q42210089-7C3387B0-1D10-4E24-864E-38F5A061DE46 Q42373188-FE61CB29-8830-4D26-A147-6A8F13C17177 Q44522018-2FE2C529-FBAD-4B23-854D-249798C233EA Q47121338-D7F5A720-50B4-4570-8B24-125591C83925 Q47983950-978D8E37-259E-4033-A4DA-B0403A209DBF Q50065301-BF2CDED7-E12E-4192-A606-CFEF415533DF Q50927361-E2629DC0-2CEF-4E6A-B7D2-DFB6B9ADFC38

P2860

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.

http://www.wikidata.org/entity/Q50758911

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Influence of immunogenicity on ...... dyloarthritis with infliximab.

@en

Influence of immunogenicity on ...... dyloarthritis with infliximab.

@nl

type

label

Influence of immunogenicity on ...... dyloarthritis with infliximab.

@en

Influence of immunogenicity on ...... dyloarthritis with infliximab.

@nl

prefLabel

Influence of immunogenicity on ...... dyloarthritis with infliximab.

@en

Influence of immunogenicity on ...... dyloarthritis with infliximab.

@nl

P1433

Q50758911-5280B9AA-976F-480E-B816-FB79BA983347

P1476

Q50758911-B6227FFE-52A9-4775-A4FF-4096FF8675B8

P2093

Q50758911-0A16898E-A125-4358-9DC9-B37788126038

Q50758911-13011035-202D-4413-8042-F008EC0222C5

Q50758911-3A3AA34E-3ECB-43FF-B55B-3EB17A55DA35

Q50758911-76F00D4A-0D6F-4C4A-8C5F-06B8DA444865

Q50758911-8692AA10-B216-46F3-8B23-B75DDC747901

Q50758911-986B5E2A-60E9-4078-975E-DBBF19651C41

Q50758911-9BC14A9C-65F5-4899-8A7E-2D4C893F227C

Q50758911-A23727F4-45BD-4E4F-9DA2-7F228F896A98

Q50758911-C02361E0-4F2C-4082-A7B2-6D8F1FD4E412

Q50758911-ED0A74FD-9EED-44CE-8425-404A4F86C9C3

P304

Q50758911-97C03792-390F-4DA3-BD76-EF7797305063

P31

Q50758911-C65883BE-E29F-4016-883E-50F7CD53ACF0

P356

Q50758911-7A1A3002-DD08-4F3A-8B18-4488030C4347

P407

Q50758911-02EEACC9-9E58-42A9-86F4-C1761A59F5C4

P433

Q50758911-C26E4350-19A4-4AB9-9763-7C215F8CBD52

P478

Q50758911-C2F36459-B171-4ECB-AA45-9C171E4F498E

P50

Q50758911-049BFCC6-6EFC-4AA2-A6BC-56E8BA3533D4

P577

Q50758911-9623FEC4-BA9A-4242-8A9B-F7600C213D65

P5875

Q50758911-23628315-84ED-456F-BA7B-1FB37090409F

P698

Q50758911-B5367BD7-3492-45F9-8856-E6AEA766CD94

P356

ANNRHEUMDIS-2011-200828

P1433

Annals of the Rheumatic Diseases

P1476

Influence of immunogenicity on ...... dyloarthritis with infliximab.

@en

P2093

Ainhoa Ruiz del Agua

http://www.w3.org/2001/XMLSchema#string

Alejandro Balsa

http://www.w3.org/2001/XMLSchema#string

Alejandro Villalba

http://www.w3.org/2001/XMLSchema#string

Chamaida Plasencia

http://www.w3.org/2001/XMLSchema#string

Daniel Nagore

http://www.w3.org/2001/XMLSchema#string

Diana Peiteado

http://www.w3.org/2001/XMLSchema#string

Dora Pascual-Salcedo

http://www.w3.org/2001/XMLSchema#string

Gema Bonilla

http://www.w3.org/2001/XMLSchema#string

Jesús Díez

http://www.w3.org/2001/XMLSchema#string

Laura Nuño

http://www.w3.org/2001/XMLSchema#string

P304

1955-1960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2011-200828

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Emilio Martin-Mola

P577

2012-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224915515

http://www.w3.org/2001/XMLSchema#string

P698

22563028

http://www.w3.org/2001/XMLSchema#string